ClinicalTrials.gg
RecruitingNCT06016517Updated Nov 16, 2026

Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis

An observational study in Arthritis, Rheumatoid, sponsored by Tufts Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Tufts Medical Center · Observational

Updated Nov 16, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
18
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 975 studies in Arthritis, Rheumatoid with a site in United States — 82 open to participants now, 122 under way, 7 of them phase 3. Arthritis, Rheumatoid · United States.

Planned enrollment
185th of 199
18 · median 200
Started
2026
with 20 others
Observational
201 of 975
29 open now
Primary completion
2028-12
later than 89 of 121 live
Registered
898th of 975
by date

Among the 975 studies in Arthritis, Rheumatoid with a site in United States, this one is the 185th largest by planned enrollment of the 199 observational ones that give a count, is one of 21 that started in 2026, is one of 201 observational ones, reaches primary completion later than 89 of the 121 other live ones, and was the 898th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

82 of the 975 studies in Arthritis, Rheumatoid with a site in United States are open now. Recruiting first, the newest first:

76 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 975 studies in Arthritis, Rheumatoid with a site in United States, or all of them as a file.
02

Study summary

The goal of this N-of-1 study is to learn about treatment for individual patients who have rheumatoid arthritis (RA,) for which many treatments are available. The treatments are different in how they work, the way they are given, side- effects, and cost. While treatment guidelines are available, finding the best treatment order of treatments is often based on physician choice. The main question this study aims to answer are:

  • What are the effects of different treatments on RA symptoms and condition for each individual patient
  • What is the effectiveness of different treatments across all patients enrolled in the N-of-1 study

Participants will be enrolled and randomized to a sequence of three U.S. Food and Drug Administration (FDA) approved RA medications: 1. etanercept, 2. adalimumab, 3. upadacitinib 4. tocilizumab. Participants will be asked to complete questionnaires about their condition and quality of life fortnightly, monthly and/or quarterly (either in clinic or remotely) and report their level of pain on alternate days (remotely).

Read the detailed description

Rheumatoid arthritis (RA) is a chronic, slowly progressive condition for which numerous treatment options are available. The therapies vary in mechanism of action, mode of administration, side- effect (adverse event) profile, and cost. While consensus treatment guidelines are available, identifying an optimal treatment sequence is often based on clinician choice with treatment changes based on tolerability and short- term outcome. The N-of-1 trial will evaluate individual participant and aggregate data.

Individual participants will be enrolled and randomized to a sequence of three U.S. Food and Drug Administration (FDA)-approved therapeutic agents etanercept, adalimumab, upadacitinib and tocilizumab.

The N-of-1- RA protocol describes patient allocation into a series of individual comparisons.

  • Patients with newly diagnosed rheumatoid arthritis following initial treatment with methotrexate (MTX). Participants will be allocated to:
  • MTX responder
  • MTX non- responder or partial responder

Eligible participants will either continue MTX or discontinue MTX, based on response to initial therapy and tolerance. Participants identified for subsequent biologic therapy will enter the biologic therapy phase of the study; with MTX either continued or not continued. This phase consists of a sequence of 4 therapeutic intervention regimens, each lasting 12-weeks.

The treatment conditions are as follows:

A. Tumor Necrosis Factor (TNF) Inhibitor biologic: etanercept 50 mg subcutaneously weekly.

B: TNF- inhibitor biologic: Adalimumab 40 mg subcutaneously every 2 weeks. C. Janus Kinase (JAK) Inhibitor: Upadacitinib 15 mg orally once daily. D. Interleukin 6 (IL-6) Inhibitor: Tocilizumab 162 mg administered SQ every 2 weeks (if there is an inadequate response to prior three biologics).

Primary Objective (individual N-of-1 trial): To generate randomized evidence about the effects of therapeutic agents on RA symptoms and disease activity to inform decision about best treatment at the end of the trial period for each participant.

Secondary Objective (aggregation of the series of N-of-1 trials): To evaluate the average relative effectiveness of therapeutic agents across all participants and explore heterogeneity of treatment effects.

For the aggregated series of N-of-1 trial, we will use the following hierarchy of endpoints.

Primary Endpoint:

  • DAS28 (CRP and ESR)

Secondary Endpoints:

  • American College of Rheumatology 20% (ACR20), 50% (ACR50) and 70% (ACR70) response
  • Routine Assessment of Patient Index Data (RAPID3) score based on participants' report of overall assessment of the disease, the level of pain, and the amount of physical disability
  • Short Form 12-Item Health Survey (SF-12) measuring the impact of disease on overall quality of life during the prior 4 weeks (physical function, pain, general and mental health, vitality, social function, physical and emotional health)
  • Report of worst pain and effect of pain on function (0-10) every other day
  • Treatment Burden Questionnaire (TBQ) administered at the end of each treatment condition

Safety Endpoint(s):

  • Number (and proportion) of patients reporting treatment emergent adverse events (TEAEs) (by MedDRA system organ class and preferred term)

For each individual N-of-1 trial, we will use the endpoints listed above, but without any pre-specified hierarchy, assuming that each patient will identify endpoints most important to them.

03

Conditions studied

  • Arthritis, Rheumatoid
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Outpatients 18 years of age or older with newly diagnosed RA following initial treatment with MTX, to which they are partial responders or non-responders.

Eligibility criteria

In order to be eligible to participate in this study, a subject must meet all the following criteria:

  • Newly diagnosed adult-onset Rheumatoid Arthritis (RA) as defined by the American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) 2021 Criteria for the Classification of RA
  • Moderately to severely active RA defined as the presence of at least 6/68 tender joints and at least 6/66 swollen joints
  • C-reactive protein (CRP) or high-sensitivity C-reactive protein (hsCRP) measurement ≥ 1 time the
  • therapy with MTX for at least the 12 weeks prior to study entry with a continuous, non-changing dose for at least 8 weeks prior to study entry but continue to exhibit active RA
  • Had to discontinue MTX due to intolerability or toxicity, irrespective of treatment duration
  • Have never received etanercept, adalimumab, upadacitinib, or tocilizumab prior to first dose of study drug.
  • Provision of in English or another language in which a validated consent form is available, or via short-form consent with the assistance of a qualified interpreter.
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • 18 years of age or older
  • Ability to take oral medication and be willing to adhere to all treatment periods
  • Patients are eligible whether their disease responded partially or inadequately to first-line MTX or if they were intolerant to first-line MTX
  • Enrollment in an insurance plan that participates in or is subscribed to this trial

An individual who meets any of the following criteria will be excluded from participation in this study:

  • History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than RA
  • Has received intra-articular, intravenous, intramuscular within 28 days prior to baseline
  • Known allergic reactions to components of any of the investigative biologic agents
  • Is currently receiving corticosteroids at doses > (greater than) 10 mg per day of prednisone (or equivalent) or have been receiving an unstable dosing regimen of corticosteroids within 2 weeks of study entry or within 6 weeks of planned randomization
  • Has experienced any of the following within 12 weeks of study entry: myocardial infarction, unstable ischemic heart disease, stroke, or have stage IV heart failure
  • Tuberculosis infection
  • or C infection
  • History of venous thromboembolic event (deep vein thrombosis, pulmonary embolism)
  • Has a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute a risk or could interfere with the interpretation of data
  • Has an estimated (eGFR) based on the most recent available serum creatinine of \< (less than) 40 milliliter per minute per 1.73 m\^2 (mL/min/1.73 m\^2)
  • Has a history of chronic liver disease with the most recent available (AST) or alanine aminotransferase (ALT) >1.5 times the ULN or the most recent available total ≥1.5 times the ULN
  • Has a history of, lymphoproliferative disease; or have signs or symptoms suggestive of possible lymphoproliferative disease, including lymphadenopathy or splenomegaly; or have active primary or recurrent malignant disease; or have been in remission from for \<5 years
  • Has been exposed to a within 12 weeks prior to planned randomization or are expected to need/receive a live vaccine during the course of the study (with the exception of herpes zoster vaccination)
  • Has a current or recent clinically serious viral, bacterial, fungal, or parasitic infection
  • Has had symptomatic herpes zoster infection within 12 weeks prior to study entry
  • Has immunocompromising condition and, in the opinion of the investigator, are at an unacceptable risk for participating in the study and using these medications
  • Has a history of active hepatitis B virus (HBV), virus (HCV), or (HIV)*
  • Has evidence of active or latent tuberculosis (TB)
  • Current hospitalization or requiring hospital admission at screening
  • Pregnant or breastfeeding
  • Of , unwilling to use effective method (highly effective contraceptive measure (e.g., combined (estrogen and progestogen containing) hormonal contraception; intrauterine device)
  • Participation in another therapeutic clinical trial for RA
  • Lack of internet access to telehealth platform

State who will determine eligibility. Note that those who are designated to determine eligibility must have appropriate training, expertise, and oversight, for example a physician PI or Co-I on a biomedical study: Eligibility will be determined by the appropriately trained and delegated physician investigator or physician Co- investigator.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
18 participants (estimated)
Patient registry
No

Interventions

  • 50 mg subcutaneously weekly

    Also known as: Enbrel

  • 40 mg subcutaneously every 2 weeks

    Also known as: Humira

  • 15 mg orally once daily with subcutaneous placebo injection every 2 weeks

    Also known as: Rinvoq

  • 162 mg administered SQ every 2 weeks

06

What researchers measure

Primary outcomes

  1. Change in Disease Activity Score (DAS) 28

    Evaluates patient and physician overall assessment of disease activity, including the number of swollen and painful joints (out of 28 joints),

    Time frame: Baseline and week 12 of each treatment period

Secondary outcomes

  1. Change in The Routine Assessment of Patient Index Data 3 (RAPID3)

    Assessment of a) function, b) pain, and c) patient global estimate of status

    Time frame: Baseline, and weeks 2, 4, 6, 8, 10, 12 of each treatment period

  2. Change in American College of Rheumatology 20 (ACR20)

    ≥20% fewer tender and swollen joints and ≥20% improvement in three of five other domains; a) patient global assessment, b) physician global assessment, c) functional questionnaire, d) pain score, and f) erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP)

    Time frame: Baseline and week 12 of each treatment period

  3. Change in American College of Rheumatology 50 (ACR50)

    ≥50% fewer tender and swollen joints and ≥20% improvement in three of five other domains; a) patient global assessment, b) physician global assessment, c) functional questionnaire, d) pain score, and f) erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP)

    Time frame: Baseline and at week 12 of each treatment period

  4. Change in American College of Rheumatology 70 (ACR70)

    ≥70% fewer tender and swollen joints and ≥20% improvement in three of five other domains; a) patient global assessment, b) physician global assessment, c) functional questionnaire, d) pain score, and f) erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP)

    Time frame: Baseline and at week 12 of each treatment period

  5. The Medical Outcome Study Short-Form 12- item Health Survey (SF-12)

    General Health Questionnaire

    Time frame: Baseline and at week 4, 8, and 12 of each treatment period

  6. Treatment Burden Questionnaire (TBQ)

    Assessment of the burden associated with taking medicine, self-monitoring, laboratory tests, doctor visits, need for organization, administrative tasks, following advice on diet and physical activity, and social impact of treatment.

    Time frame: At week 36

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

Of 236 non-industry observational studies under Arthritis, Rheumatoid, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 122. This study's planned 24 months is below that.

Counting every sponsor, half of 391 studies reached it within 50 months; a quarter within 25 and three quarters within 113.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: start Sep 2026 → Dec 2026 and primary completion Sep 2028 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2023
First posted
Aug 29, 2023
StartEst.
Dec 1, 2026was Sep 2026
Primary completionEst.
Dec 1, 2028was Sep 2028
CompletionEst.
Dec 15, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 16, 2026
Sites
Tufts Medical Center is now Recruiting
Nov 16, 2026
Start date
Sep 1, 2026→Dec 1, 2026
Nov 16, 2026
Primary completion
Sep 1, 2028→Dec 1, 2028
Nov 16, 2026
Contact
Study contact changed: m•••@tuftsmedicine.org · •••9870→m•••@tuftsmedicine.org · •••9983; h•••@tuftsmediaclcenter.org→h•••@tuftsmedicine.org. See the current contact
Nov 16, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Tufts Medical Center · Boston, United StatesContact added (no phone or email listed)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Not yet recruiting→Recruiting
    Tufts Medical Center is now Recruiting
    Start date Sep 1, 2026→Dec 1, 2026
    Primary completion Sep 1, 2028→Dec 1, 2028
    Contact Study contact changed: m•••@tuftsmedicine.org · •••9870→m•••@tuftsmedicine.org · •••9983; h•••@tuftsmediaclcenter.org→h•••@tuftsmedicine.org. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Tufts Medical Center · Boston, United StatesContact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06016517
Responsible party
Sponsor
First posted
Aug 29, 2023
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 15, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Marisha Palm, MSc, PhD
Contact
marisha.palm@tuftsmedicine.org
3203399983
Harry P Selker, MD
Contact
harry.selker@tuftsmedicine.org
6176365009
Harry P Selker, MD
principal investigator · Tufts Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion